Novartis (NYSE: NVS) has been granted approval for the first pediatric-specific dosage to be used to treat a pediatric tumor by the U.S. Food and Drug Administration. A new formulation of its anti-cancer drug Afinitor will be used to treat a rare brain tumor called subependymal giant cell astrocytoma or SEGA in children aged one […]
Novartis (NYSE:NVS) has inked a deal with the University of Pennsylvania to invest $20 million to develop a stand-alone research and development center at the university to commercialize novel cellular immunotherapies for cancer that will create at least 100 jobs. The move is the largest academic-industry agreement of its kind for Penn to date, according […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The U.S. Food and Drug Administration has approved a drug developed by Novartis (NYSE: NVS) for advanced breast cancer in post-menopausal women. The Swiss pharmaceutical company’s drug has been approved to be used in combination with Aromasin a drug used to treat menopausal women with early breast cancer who have already been treated with tamoxifen, […]
The U.S. Food and Drug Administration has approved a revised label for cancer drug Gleevec following a clinical study that showed better results with prolonged use of the drug compared with the 12 months that has been recommended. The U.S. regulator also granted regular approval of Gleevec. Marketed by Swiss pharmaceutical company Novartis Pharmaceuticals (NYSE:NVS) […]
If a flu pandemic strikes the United States, a Novartis (NYSE:NVS) plant in North Carolina now stands ready to respond with vaccine techniques that offer speed and scalability advantages over traditional vaccine-making methods. Novartis’ vaccine facility in Holly Springs, North Carolina today became the first cell culture vaccine facility authorized by the U.S. Food and […]
The movie “Contagion” is fiction, but ask Novartis (NYSE:NVS) executive Russell Thirsk and he’ll tell you the threats it depicts are quite real. For those who don’t know, “Contagion” tells the story of the worldwide spread of a virulent virus that goes on to kill millions. Thirsk is site head of Novartis’ new vaccine facility […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Among today's current medical news: Novartis wins FDA approval on a new pancreatic cancer drug; Vermont on its way to introducing single payer health care system; one nurses strike in California starts while another in Massachusetts is averted; and sex, coffee and six other things that can kill you, according to a new study.
Duke University’s Human Vaccine Institute will work with Novartis (NYSE:NVS) to rapidly develop a vaccine in case of a pandemic virus, according to a new five-year agreement. The team of Duke and Novartis investigators will have access to resources at both Duke University and Novartis’ vaccine manufacturing facility in Holly Springs, North Carolina. The facilities […]